Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this study is to compare the relative bioavailability of Losartan potassium/Hydrochlorothiazide 100/25 mg tablets (manufactured by Teva Pharmaceutical Industries, Ltd. and distributed by Teva Pharmaceuticals USA) with that of Hyzaar® 100/25 mg tablets (Merck) in healthy, adult, non-smoking subjects under non-fasting conditions.
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA Bioequivalence Statistical Methods
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Generic Test Product | Experimental | Losartan potassium/Hydrochlorothiazide 100/25 mg Tablets |
|
| Reference Listed Drug | Active Comparator | Hyzaar® 100/25 mg Tablets |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Losartan potassium/Hydrochlorothiazide | Drug | 100/25 mg Tablets |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Cmax of Losartan(Maximum Observed Concentration of Drug Substance in Plasma) | Bioequivalence based on Losartan Cmax. | Blood samples collected over a 48 hour period. |
| AUC0-t of Losartan(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) | Bioequivalence based on Losartan AUC0-t. | Blood samples collected over a 48 hour period. |
| AUC0-inf of Losartan(Area Under the Concentration-time Curve From Time Zero to Infinity) | Bioequivalence based on Losartan AUC0-inf. | Blood samples collected over a 48 hour period. |
| Cmax of Hydrochlorothiazide(Maximum Observed Concentration of Drug Substance in Plasma) | Bioequivalence based on Hydrochlorothiazide Cmax. | Blood samples collected over a 48 hour period. |
| AUC0-t of Hydrochlorothiazide(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) | Bioequivalence based on Hydrochlorothiazide AUC0-t. | Blood samples collected over a 48 hour period. |
| AUC0-inf of Hydrochlorothiazide(Area Under the Concentration-time Curve From Time Zero to Infinity) | Bioequivalence based on Hydrochlorothiazide AUC0-inf. | Blood samples collected over a 48 hour period. |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| James D Carlson, Pharm D | PRACS Institute, Ltd. | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| PRACS Institute, Ltd. | Fargo | North Dakota | 58104 | United States |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Losartan/HCTZ (Test) First | 100/25 mg Losartan potassium/Hydrochlorothiazide test product dosed in first period followed by 100/25 mg Hyzaar® Tablets reference product dosed in the second period. |
| FG001 | Hyzaar® (Reference) First | 100/25 mg Hyzaar® Tablets reference product dosed in first period followed by 100/25 mg Losartan potassium/Hydrochlorothiazide test product dosed in the second period. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First Intervention |
|
| ||||||||||||||||||
| Washout of 7 Days |
| |||||||||||||||||||
| Second Intervention |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Losartan/HCTZ (Test) First | 100/25 mg Losartan potassium/Hydrochlorothiazide test product dosed in first period followed by 100/25 mg Hyzaar® Tablets reference product dosed in the second period. |
| BG001 | Hyzaar® (Reference) First |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Cmax of Losartan(Maximum Observed Concentration of Drug Substance in Plasma) | Bioequivalence based on Losartan Cmax. | All participants that completed the study had their samples analyzed. | Posted | Mean | Standard Deviation | ng/mL | Blood samples collected over a 48 hour period. |
|
Adverse event data was collected over the course of the study, which was approximately 2 weeks in duration.
Volunteers were monitored throughout the study for any adverse experiences. AEs were collected through both solicited and unsolicited methods. The volunteers were encouraged to report signs, symptoms, and any changes in health to the clinic staff.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Losartan/HCTZ (Test) | 100/25 mg Losartan potassium/Hydrochlorothiazide test product dosed in either period. |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Associate Director, Biopharmaceutics | TEVA Pharmaceuticals, USA | 1-866-384-5525 | clinicaltrialqueries@tevausa.com |
Not provided
| ID | Term |
|---|---|
| C505809 | hydrochlorothiazide, losartan drug combination |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Losartan potassium/Hydrochlorothiazide |
| Drug |
100/25 mg Tablets |
|
|
| NOT COMPLETED |
|
|
| NOT COMPLETED |
|
100/25 mg Hyzaar® Tablets reference product dosed in first period followed by 100/25 mg Losartan potassium/Hydrochlorothiazide test product dosed in the second period.
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Number | participants |
|
| Region of Enrollment | Number | participants |
|
| Units | Counts |
|---|---|
| Participants |
|
|
|
| Primary | AUC0-t of Losartan(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) | Bioequivalence based on Losartan AUC0-t. | All participants that completed the study had their samples analyzed. | Posted | Mean | Standard Deviation | ng*h/mL | Blood samples collected over a 48 hour period. |
|
|
|
|
| Primary | AUC0-inf of Losartan(Area Under the Concentration-time Curve From Time Zero to Infinity) | Bioequivalence based on Losartan AUC0-inf. | All participants that completed the study had their samples analyzed. | Posted | Mean | Standard Deviation | ng*h/mL | Blood samples collected over a 48 hour period. |
|
|
|
|
| Primary | Cmax of Hydrochlorothiazide(Maximum Observed Concentration of Drug Substance in Plasma) | Bioequivalence based on Hydrochlorothiazide Cmax. | All participants that completed the study had their samples analyzed. | Posted | Mean | Standard Deviation | ng/mL | Blood samples collected over a 48 hour period. |
|
|
|
|
| Primary | AUC0-t of Hydrochlorothiazide(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) | Bioequivalence based on Hydrochlorothiazide AUC0-t. | All participants that completed the study had their samples analyzed. | Posted | Mean | Standard Deviation | ng*h/mL | Blood samples collected over a 48 hour period. |
|
|
|
|
| Primary | AUC0-inf of Hydrochlorothiazide(Area Under the Concentration-time Curve From Time Zero to Infinity) | Bioequivalence based on Hydrochlorothiazide AUC0-inf. | All participants that completed the study had their samples analyzed. | Posted | Mean | Standard Deviation | ng*h/mL | Blood samples collected over a 48 hour period. |
|
|
|
|
| 0 |
| 80 |
| 0 |
| 80 |
| EG001 | Hyzaar® (Reference) | 100/25 mg Hyzaar® Tablets reference product dosed in either period. | 0 | 80 | 0 | 80 |
The Principal Investigator is not permitted to discuss or publish trial results.